Prothena Corporation, a clinical stage biotechnology company focused on the discovery, development and commercialisation of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, has promoted Tara Nickerson to Chief Business Officer. She takes responsibility for leading corporate and business development, as well as alliance management efforts at the Dublin, Ireland-based company.
Prior to this promotion, Nickerson was Head of Corporate and Business Development at the company, where she was instrumental during Prothena's demerger from Elan Corporation Limited.
'Tara has brought significant business and biotechnology expertise to Prothena since our inception. As our Chief Business Officer, she can provide critical leadership to advance our research and clinical pipeline,' said Dale Schenk, President and Chief Executive.
Before joining Prothena, Nickerson was Vice President and Head of Business Development at Elan Pharmaceuticals. She was previously a Senior Scientist at Axys Pharmaceuticals (acquired by Celera Genomics).
